AbbVie
ABBV
$189.77
Share price
1.14%
Change (1 day)
13.96%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
P/S ratio for AbbVie (ABBV)
P/S ratio as of July 2025 (TTM): 5.84
According to AbbVie's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 229. At the end of 2025 the company had a P/S ratio of 6.33.
P/S ratio history for AbbVie from 2012 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 6.33 | 13.37% |
| 2024 | 5.58 | 10.86% |
| 2023 | 5.04 | 2.32% |
| 2022 | 4.92 | 15.58% |
| 2021 | 4.26 | 3.14% |
| 2020 | 4.13 | 4.92% |
| 2019 | 3.94 | -5.43% |
| 2018 | 4.16 | -23.93% |
| 2017 | 5.47 | 37.85% |
| 2016 | 3.97 | -4.86% |
| 2015 | 4.17 | -20.04% |
| 2014 | 5.22 | 16.95% |
| 2013 | 4.46 | 51.93% |
| 2012 | 2.94 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.33 | -60.09% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.01 | -65.61% | 🇺🇸 USA |
 Eli Lilly LLY | 14.2 | 143.81% | 🇺🇸 USA |
 Amgen AMGN | 4.68 | -19.91% | 🇺🇸 USA |
 Gilead Sciences GILD | 4.81 | -17.72% | 🇺🇸 USA |
 Biogen BIIB | 2.01 | -65.65% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 1.93 | -67.01% | 🇬🇧 UK |
 AstraZeneca AZN | 4.01 | -31.46% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 5.28 | -9.62% | 🇺🇸 USA |